Bolt Biotherapeutics, Inc.(BOLT)

$3.98—

Chart

Bolt Biotherapeutics, Inc.(BOLT)

NASDAQ

$3.98—

Chart Studio

BOLT(BOLT)

BOLT

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-3.39

Aug 13, 2026 · Reports before open

Revenue Estimate

$500,000

Analyst Sentiment

Wall St. Consensus

Hold

8 analysts·Limited coverage

Score

3 Buy (38%)5 Hold (63%)0 Sell (-1%)

Rating Breakdown

Strong Buy

00%

Buy

338%

Hold

563%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$1.00

-74.9%

Consensus

$4.00

+0.5%

Bull

$7.00

+75.9%

12-Month Target Range8 analysts

$1.00$4.00$7.00

Current $3.98Consensus

Current Price

$3.98

Upside to Consensus

$0.02

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+106.22%

EPS—

FY2028

Rev+71.43%

EPS—

FY2029

Rev+0.00%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$1M	$2M	$4M	$4M	$4M
Low	$1M	$2M	$4M	$4M	$4M
High	$1M	$2M	$4M	$4M	$4M
EBITDA Avg	$-1M	$-2M	$-4M	$-4M	$-4M
Low	$-1M	$-2M	$-4M	$-4M	$-4M
High	$-1M	$-2M	$-4M	$-4M	$-4M
EBIT Avg	$-1M	$-2M	$-4M	$-4M	$-4M
Low	$-1M	$-2M	$-4M	$-4M	$-4M
High	$-1M	$-2M	$-4M	$-4M	$-4M
Net Income Avg	$-30M	$-48M	$-58M	$-66M	$-75M
Low	$-30M	$-72M	$-58M	$-66M	$-75M
High	$-30M	$-2M	$-58M	$-66M	$-75M
EPS Avg	$-15.88	$-19.93	$-30.84	$-35.53	$-40.09
Low	$-15.88	$-38.68	$-30.84	$-35.53	$-40.09
High	$-15.88	$-1.18	$-30.84	$-35.53	$-40.09
Analysts (Rev / EPS)	2 / 2	2 / 2	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$500,000	$500,000	$100,000	$100,000	$100,000	$26,000
Low	$500,000	$500,000	$100,000	$100,000	$100,000	$26,000
High	$500,000	$500,000	$100,000	$100,000	$100,000	$26,000
EBITDA Avg	$-500,000	$-500,000	$-100,000	$-100,000	$-100,000	$-26,000
Low	$-500,000	$-500,000	$-100,000	$-100,000	$-100,000	$-26,000
High	$-500,000	$-500,000	$-100,000	$-100,000	$-100,000	$-26,000
EBIT Avg	$-500,000	$-500,000	$-100,000	$-100,000	$-100,000	$-26,000
Low	$-500,000	$-500,000	$-100,000	$-100,000	$-100,000	$-26,000
High	$-500,000	$-500,000	$-100,000	$-100,000	$-100,000	$-26,000
Net Income Avg	$-6M	$-6M	$-4M	$-4M	$-3M	$-13M
Low	$-6M	$-6M	$-4M	$-4M	$-3M	$-13M
High	$-6M	$-6M	$-4M	$-4M	$-3M	$-13M
EPS Avg	$-3.20	$-3.18	$-2.00	$-2.20	$-1.40	$-6.80
Low	$-3.20	$-3.18	$-2.00	$-2.20	$-1.40	$-6.80
High	$-3.20	$-3.18	$-2.00	$-2.20	$-1.40	$-6.80
Analysts (Rev / EPS)	2 / 2	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Oct 20, 2025H.C. Wainwright

Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright

Target:$7.00

+21.7%from $5.75

May 15, 2024Leerink Partners

Leerink Partners Downgrades Bolt Biotherapeutics, Inc. (BOLT) to Market Perform 'on Uncertain Platform Outlook'

Target:$1.00

-24.2%from $1.32

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance